Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | HJC0152 |
| Synonyms | |
| Therapy Description |
HJC0152 inhibits STAT3, potentially leading to induction of apoptosis and decreased proliferation, migration, invasion, and tumor growth (PMID: 30588091, PMID: 35085771). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| HJC0152 | HJC-0152|HJC 0152 | STAT3 Inhibitor 26 | HJC0152 inhibits STAT3, potentially leading to induction of apoptosis and decreased proliferation, migration, invasion, and tumor growth (PMID: 30588091, PMID: 35085771). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|---|---|---|---|---|---|---|
| EML4 - ALK ALK G1202R | lung non-small cell carcinoma | sensitive | HJC0152 | Preclinical - Cell culture | Actionable | In a preclinical study, HJC0152 treatment decreased Stat signaling, migration, and invasion in a non-small cell lung cancer cell line expressing EML4-ALK and ALK G1202R in culture (PMID: 35085771). | 35085771 |
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|